NVCRNovoCure Limited
Price
+15%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality strong, a flag to check, growing in the filings, the market undecided.
We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Our therapy is delivered through a medical device. Our key priorities are to drive commercial adoption of Optune Gio®, Optune Lua®, and Optune Pax®, our commercial TTFields therapy devices, obtain regulatory approval to market TTFields therapy devices in new indications, such as brain metastases from non-small cell lung cancer ("NSCLC"), and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
NovoCure Limited (NVCR) reported revenue of $184M in Q2 2026 (quarter ended Jun 30, 2026), up 16% from the same quarter a year earlier. That came with a gross margin of 78% and net loss of $16M. For the full year FY2025, revenue was $655M (+8.3% year on year) and net income −$136M. Its largest region in Q2 2026 was United States at $103M, 62% of the disclosed total, well ahead of Germany at 14%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 9, 2026Timothy Scannell, a current director of NovoCure Limited (the “Company”), has retired from the Board and his seat was formally vacated pursuant to the Company’s Articles of Association effective September 2, 2026.Director or officer change · Form 8-K
- Sep 1, 2026In mid-August 2026, NovoCure Limited (the "Company," "we," or "us") through a subsidiary, became aware of unauthorized access to some of its information systems.Other event · Form 8-K
- Jun 5, 2026Election of Director s On June 3, 2026, NovoCure Limited (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $165.4MThe company’s own SEC segment disclosure.
- United States$103.0M62%
- Germany$23.3M14%
- France$21.3M13%
- Japan$11.8M7%
- China$6.0M4%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.